



Published in final edited form as:

Oncogene. 2020 July ; 39(27): 5068–5081. doi:10.1038/s41388-020-1342-0.

Ribosomal protein S11 influences glioma response to TOP2 poisons

Chidiebere U Awah¹, Li Chen¹, Mukesh Bansal², Aayushi Mahajan³, Jan Winter⁴, Meeki Lad⁵, Louisa Warnke¹, Edgar Gonzalez-Buendia¹, Cheol Park¹, Zhang Daniel¹, Eric Feldstein¹, Dou Yu¹, Markella Zannikou¹, Irina V. Balyasnikova¹, Regina Martuscello⁶, Silvana Konerman⁷, Balázs Györfy⁸, Kirsten B Burdett⁹, Denise M Scholtens⁹, Roger Stupp¹, Atique Ahmed¹, Patrick Hsu⁷, Adam M Sonabend^{1,10*}

¹Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University Chicago.

²Psychogenic Inc., Paramus, New Jersey

³Department of Neurological Surgery, Columbia University Medical Center, Columbia University, New York City.

⁴Functional Genomics and Signaling, German Center for Cancer Research, Heidelberg, Germany.

⁵Mailman School of Public Health, Columbia University, New York City.

⁶Department of Pathology, Columbia University Medical Centre, Columbia University New York City.

⁷Molecular and Cell Biology, Salk Institute, La Jolla, California.

⁸MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, and Semmelweis University 2nd Dept. of Pediatrics.

⁹Department of Preventive Medicine, Northwestern University, Chicago.

Abstract

Topoisomerase II poisons are one of the most common class of chemotherapeutics used in cancer.

We and others had shown that a subset of glioblastomas (GBM), the most malignant of all primary

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

^{10*}Corresponding author: Adam M Sonabend MD, Department of Neurosurgery Northwestern University Feinberg School of Medicine adam.sonabend@nm.org.

Author's contribution

AS and CUA conceived the idea of this project. CUA, AM, LC performed the genome scale CRISPR screen. JW and CUA performed the screen analysis. MB and CUA performed the combinatorial analysis to predict biomarkers. CUA performed the single gene editing and all validations. ML contributed to organizing and curating the large-scale data used in this work. CUA, LW and DZ performed western blots. EF contributed in cell culture. DY and CUA performed the immunohistochemistry, EBG and CP transduced lentivirus with RPS11 overexpression vector. MZ and CUA performed the flow cytometry analysis. SK contributed to the CRISPR screen. IB contributed reagents and corrected the manuscript. CUA and RM performed the DNA damage analysis on edited cells and GBM cell lines respectively and LC performed 53BP1 staining. BG, KMB, DMS performed oversight statistical analysis. AS, PH, AH supervised the project. CUA, MZ and AS prepared figures. CUA and AS wrote the manuscript.

Declaration of Interest

The authors declare conflict of interest in that a patent application has been submitted in regard to the findings here in this article.

brain tumors in adults, are responsive to TOP2 poisons. To identify genes that confer susceptibility to this drug in gliomas, we performed a genome-scale CRISPR knockout screen with etoposide. Genes involved in protein synthesis and DNA damage were implicated in etoposide susceptibility. To define potential biomarkers for TOP2 poisons, CRISPR hits were overlapped with genes whose expression correlates with susceptibility to this drug across glioma cell lines, revealing ribosomal protein subunit RPS11, 16, 18 as putative biomarkers for response to TOP2 poisons. Loss of RPS11 led to resistance to etoposide and doxorubicin and impaired the induction of pro-apoptotic gene APAF1 following treatment. The expression of these ribosomal subunits was also associated with susceptibility to TOP2 poisons across cell lines from gliomas and multiple other cancers.

Keywords

CRISPR; Glioblastoma (GBM); Topoisomerase II poisons (TOP2: etoposide, doxorubicin); DNA damage and repair response; γ H2AX (gamma H2AX phosphorylation) FANCB; Protein Synthesis; Ribosomal proteins subunits: (RPS11, 16, and 18); APAF1; Pro-(BID, CASPASE3/7) and anti-apoptotic effectors (BCL2)

Introduction

Glioblastoma (GBM) remains the most lethal of all primary brain tumors in adults. The standard therapy for this disease includes maximal surgical resection, radiation therapy, chemotherapy with the alkylating agent temozolomide, and more recently, the use of tumor-treating electrical field therapy. Despite this multi-modal therapy, the median survival is approximately 2 years (1). Such a uniform therapeutic approach contrasts with the molecular diversity of this disease. GBM are notorious for their unpredictable response to therapies, which ultimately contributes to the poor prognosis. To characterize this complexity, several iterations of molecular classifications have been performed based on gene expression patterns, genetic alterations, and DNA methylation (2–4). In this context, major efforts are focused on utilizing gene expression patterns to predict unique tumoral vulnerability and inform the choice of specific drugs for individual patients.

Topoisomerase II (TOP2) enzymes that unwind DNA during replication and transcription to relax the torsional stress of DNA folding. TOP2 poisons etoposide and doxorubicin, which induce double-strand DNA breaks, are widely used for different cancers (5–6). Etoposide is typically used for testicular cancer and small cell lung cancer as these tumors are considered susceptible to this drug. Whereas etoposide and doxorubicin are not commonly used for gliomas, these drugs are also effective in an elusive subset of these tumors (7–8). Clinical trials in recurrent gliomas show that some patients responded to etoposide-containing regimens, and this response also led to a survival benefit (9–11). We previously showed that some human glioma cell lines are as susceptible to etoposide as testicular cancer cell lines (the most susceptible cancer to this drug), suggesting that the histological diagnosis might be less important than individual tumor biology predicting response to this drug (7). In this context, the criteria and molecular signatures for refining patient selection remain a major challenge for effective therapy using TOP2 poisons for cancer and gliomas in particular, as there are no reliable predictive biomarkers for these drugs.

Rapid advances of the CRISPR-Cas9 genome editing technology have allowed unbiased interrogation of the mammalian genome and efficient linking of genotype and function (12–13). CRISPR-based knock-out (KO) screening libraries have been optimized to maximize on-target gene editing. Through the introduction of 3–4 independent sgRNAs per gene, functional consequences resulting from gene inactivation can be assessed, minimizing false-positive results from off-target KO (12–15). Taking advantage of this technology to investigate the molecular mechanisms involved in glioma susceptibility to etoposide, we performed a genome scale CRISPR KO screen in cells undergoing treatment with this drug. In order to discover a biomarker for personalizing this therapy for GBM, we have overlapped the genes that conferred etoposide susceptibility in our CRISPR screen, with genes whose expression is associated with susceptibility to this drug across glioma cell lines. This approach led to a short list of biomarker candidates that are experimentally implicated and correlatively associated with susceptibility to this drug. Our results show that ribosomal subunit proteins (RPS11, RPS16 and RPS18) influence with glioma susceptibility to TOP2 poisons, and that the expression of these genes is associated with response to TOP2 poisons across cell lines from multiple cancers. RPS11 appears to modulate translation in these tumors. In particular, we observed that RPS11 loss led to resistance to TOP2 poisons and was associated with an impaired induction of pro-apoptotic protein APAF1 following etoposide. This study introduces RPS11 as a promising biomarker for response to TOP2 poisons, and suggests protein synthesis is involved in response to these drugs.

Material & Methods

SgRNA design and lentiviral production.

For loss of function screen, we used the Brunello Library that contains 70,000 sgRNA which covers the 20,000 genes in the human genome at the coverage rate of 3–4sgRNA/gene plus 10,000 sgRNA which are non-targeting controls (12). To prepare the library, we used the protocol as described (14). Briefly, the HEK293T cells are grown to 70% confluence. The cells are harvested and seeded into T225 flask for 20–24hrs. The cells are mixed with Opti-MEMI reduced serum with pMD2.G –5.2µg/ml, psPAX-10.4µg/ml, Lipofectamine plus reagent and incubated with the cells for 4hrs. At the end of 4hrs the media is collected and filtered with 0.45µM filters. The virus is aliquoted and stored at –80C.

Viral titer.

To determine viral titer, 3×10^6 of SNB19 cells are seeded into 12-well plate in 2ml. Supernatant containing virus are added at 400µl, 200µl, 100µl, 75µl, 50µl, 25µl and 8µg/µl of polybrene is and spininfected at 1000g at 33°C for 2hrs. Cells then are incubated at 37°C. After 24hrs the cells are harvested and seeded at 4×10^3 with puromycin for 96hrs with a well containing cells that were not transduced with any virus. After 96hrs the titre glo is used to determine cell viability at MOI 21%. At the multiplicity of infection (MOI) of 21% we are able to infect 1 sgRNA/cell.

Large scale cell culture and expansion.

To perform the CRISPR screening, SNB19 cells were expanded to 500million and then spininfected with 70,000sgRNA. After spininfection, the cells are selected with 0.6µg/ml of

puromycin for 4days. This selection is aimed at the cells that have been rightly integrated with the sgRNA that incorporates the puromycin cassette into their genome. We achieved an MOI of 21% in two independent screens. At the end of day 4, about 150million cells survived the selection. We used 50 million of selected cells for the extraction of genomic DNA. The base sgRNA representation is obtained by amplification of the sgRNA with unique barcoded primers. The remaining 100million cells were expanded for 2days, once cells grew to 200 million. 100 million of cells were treated with etoposide at concentration of 5 μ M for 14 days, and the remaining 100 million were treated with DMSO for 14 days and served as control. After 14days, the cells were harvested, the gDNA extracted, and the sgRNA amplified with another unique barcoded primer.

DNA extraction and PCR amplification of pooled sgRNA

Briefly, the genomic DNA (gDNA) were extracted with the Zymo Research Quick-DNA midiprep plus kit (Cat No: D4075). gDNA was further cleaned by precipitation with 100% ethanol with 1/10 volume 3M sodium acetate, PH 5.2 and 1:40 glycogen co-precipitant (Invitrogen Cat No: AM9515). The gDNA concentration were measured by Nano drop 2000 (Thermo Scientific). The PCR were set up as described (14). The sgRNA library, puromycin, DMSO and etoposide selected guide RNA were all barcoded with unique primers as previously described.

Next Generation Sequencing.

The sgRNAs were pooled together and sequenced in a Next generation sequencer (Next Seq) at 300 million reads for the four sgRNA pool aiming at 1,000reads/sgRNA. The samples were sequenced according to the Illumina user manual with 80 cycles of read 1 (forward) and 8 cycles of index 1(14). 20% PhiX were added on the Next Seq to improve library diversity and aiming for a coverage of >1000reads per SgRNA in the library.

CRISPR screen data analysis.

All data analysis was performed with the bioinformatics tool CRISPR Analyzer (45). Briefly, the sequence reads obtained from Next Seq were aligned with human genome in quality assessment to determine the percentage that maps to the total human genome. To set up the analysis, the sgRNA reads (library, puromycin, DMSO and etoposide) replicates were loaded unto the software. The sgRNA that does not meet a read count of 20 is removed. Hit calling from the CRISPR screen was done based on sgRSEA enriched, $p < 0.01$ was used for significance based on Wilcoxon test.

Gene Ontology

We used DAVID (42,43) and analyzed for the biological pathways that were enriched for etoposide and genes that controls glioma susceptibility to TOP2.

Immunofluorescence.

Northwestern University institutional animal care facility (IACUC) approved the animal experiments. GBM patient-derived xenograft (PDX) lines, MES83, U251, GBM6, GBM12 and GBM43, were all implanted into brain of nude mice using stereotactic device and

following institutional animal care facility protocols. Once tumor implanted (4–6weeks), we sacrificed the animal and fixed the brain with 4% PFA. Using sucrose gradient, we dehydrated the tissue and mounted with OCT. Tissue section were cut at 5 μ M. We washed the tissue in PBS-tween20, and incubated with anti-RPS11, 16 and 18 (1:100) (Supplementary List 4) overnight at room temperature. Tissue were blocked in 3% BSA in PBS and incubated for 2hrs. Using anti-rabbit Alexa 488 and DAPI mounting media, we stained the proteins and obtained images on confocal microscope. The following Abcam antibodies were used for immunofluorescence: Anti-gamma H2A.X (phospho S139) antibody (Cat. # ab11174) and Anti-53BP1 antibody [EPR2172(2)] (Cat. # ab175933).

Single gene editing.

To edit FANCB and RPS11, we used single guide RNAs that were enriched for both genes as well as the non-targeting controls. Briefly, these guides were synthesized by Synthego and following the protocol, we prepared the ribonucleoprotein complexes by mixing the guides (180pmol) with recombinant Cas9 protein (Synthego) 20pmol in 1:2 ratio. The complexes were allowed to form at room temp for 15mins, and then 125 μ L of Opti-MEM I reduced serum medium and 5 μ L of lipofectamine Cas9 plus reagent were then added. Both, the cells and the formed ribonucleoprotein complexes, were seeded at the same time with 150,000 SNB19 cells in a T25 flask. The cells were incubated for 4days. After 4 days, the cells were harvested, and downstream analysis were performed to prove the editing of the genes.

T7E1 cleavage assay.

To confirm the efficiency of the edit, we extracted the gDNA from the edited cells as described from Gene Art (Cat No: A24372) and then using primers for the on-target and the off targets of FANCB and RPS11 respectively and amplified them by PCR. The PCR cycle used has been described in Gene Art (Cat no: A24372). The amplified bands were gel extracted and hybridized as described in Gene Art (Cat no: A24372). Subsequently, we incubated the hybridized amplicon with T7E1 (NEB: M0302). The cleaved bands were resolved on 2% agarose gel.

Western blot.

To confirm the loss of protein expression of the gene of interest following editing, we extracted the proteins using M-PER (Thermoscientific: 78501) and cocktail of phosphatase and protease inhibitors. The cells were lysed using water bath ultrasonicator for 4mins. Cell lysate were cleared by centrifugation. We measured the concentration of protein in lysates. Denatured lysates were loaded into 4–20% Tris- glycine gels (Novex) and separated at 180V for 2hrs. The gels were transferred unto a PVDF membrane by semi-dry blotting for 1hr. We blocked the membrane in 5% non-fat milk TBST buffer for 30mins and incubated with primary antibodies RPS11 (1:500), FANCB (1:500), GAPDH or ACTB (1:1500) in 5% BSA respectively over night shaking at 4°C. Primary antibodies were removed and we added the secondary polyclonal HRP (1:20,000) in TBST and incubated shaking for 2hrs at room temp. The membranes were washed 6X in TBST and then developed with ECL (Cat No: 1705061) and band imaged on a Bio-Rad Chemi-doc imaging system.

Viability assay.

The edited cells (FANCB, RPS11, non-targeting control and wild type unedited SNB19) were seeded at 4,000 cells/well in a 96 well plate and treated them with 5 μ M etoposide and doxorubicin or DMSO for 72hrs. For GBM PDX lines, we seeded them as well at 4,000cells/well in a 96 well and then added etoposide at a range of 2–40 μ Mfor 72hrs. Titre glo was added following incubation with drugs. (Cat No: G7572) and the viability of cells was analyzed 5 min later by measuring the luminescence. We normalized the intensity against DMSO treated cells of each cell line or PDX or the edited cell and then determined the survival. Pictures of these cells were also taken as shown in the source data figures.

Click-it Plus OPP Assay, Apoptosis Assay and Flow Cytometry.

To determine if nascent protein synthesis is impaired upon editing of RPS11 and FANCB. We seeded edited cells SgRPS11, SgFANCB, wild type SNB19 and the non-targeting controls in a 96 well plate with black covers overnight at 4,000cells/well. To determine if etoposide impacted nascent protein synthesis and apoptosis on the GBM PDX lines, we treated them with DMSO or etoposide 5 μ M for 24hrs. Following the protocol from Life technologies (Cat No: C10456), we added the Click-it OPP (1:1000), or Caspase 3/7 (Cat no: C10427) or with antibodies against BID, BCL2 or APAF1 for 30mins. After washing cells were fixed and primary antibodies were detected secondary antibodies conjugated to Alexa Flour 488. The fluorophore intensity was measured by flow cytometry (LSR Fortessa 1 analyzer). As a complementary approach, the labelled cells were also imaged in a fluorescent microscope (Nikon Ti2 Widefield).

qRT-PCR.

Wild type and the sgRPS11 edited SNB19 cells as well as the non-targeting controls cells were treated with and without etoposide (5 μ M) for 24hrs. The total RNA was extracted using Zymo Research kit (Direct-zol RNA Miniprep Plus, Cat no: R2070). The quality of the RNA was determined by RNA pico bioanalyzer measuring the 18S and 28S ribosome. Using the superscript III first strand synthesis system (Cat no: 18080–051), we generated cDNA and performed qPCR with APAF1 and ACTB primers in triplicates and fold change of expression of APAF1 were normalized against actin B (ACTB).

DNA damage assay.

For the analysis of DNA damage cells were seeded at 4,000/well together with wild type cells and the non-targeting control edited cells. Cells were treated with 5 μ M etoposide or DMSO for 24 hrs. The cells were harvested and then using the protocol from BD Science (material no: 560477), the cells were fixed with 200 μ L of 4% PFA for 10mins, blocked in 10% BSA for 2hrs at room temperature, washed with PBS, and then 1:10 H2A.X antibody phospho S139 (ab11174) or 53BP1 antibody (ab175933) were added and incubated for overnight. After washing, the primary antibody was detected by goat anti-mouse antibody conjugated to Alexa Flour 488(Thermofisher: #A-11001). DAPI nuclear stain in mounting media was used to counterstain nucleus. We obtained images of foci of gamma H2AX and 53BP1 using Nikon element imaging software (NIS-element), we counted the foci inside the nucleus.

GBM patient derived xenograft culture.

The patients derived xenografts GBM 12, GBM6, GBM83, and GBM43 were used in this study. Briefly, all the GBM PDX cells were all authenticated, they were cultured in 1% FBS in DMEM media. SNB19 were grown in 10% FBS in MEM media containing, essential amino acids, sodium pyruvate and 1% glutamine. U251 were grown in 10% FBS DMEM media. The cells were all grown to 80% confluency and then used for downstream analysis.

Statistical analysis.

Briefly, the CRISPR analysis were all performed with CRISPR Analyzer which contains 8 statistical analysis for hit calling. All our experiments were performed in at least two independent experiments with multiple replicates. All bar charts in the manuscript were built with Graph Pad prism software 8 (San Diego, CA, USA). The statistical analysis performed for each figure are listed in the figure of the accompanying figures.

Reagents used.

All reagents used in this work are listed in Supplementary List.

Results

Translation-related genes and DNA damage repair pathways are implicated in glioma susceptibility to etoposide by large-scale CRISPR screen.

We performed a genome-wide scale CRISPR KO screen using a clinically relevant dose of etoposide (5 μ M) to identify genes that influence human glioma susceptibility to etoposide. Several clinical studies quantified intra-tumoral concentrations of etoposide in gliomas and brain metastases following systemic administration of this drug and found a concentration range between 2–6 μ M in the tumor tissue (16–18). Moreover, the treatment with etoposide at 5 μ M for 72 hrs led to 80% cells death in susceptible glioma cell line SNB19, whereas resistant cell lines showed minimal cell death (Fig 1A). Thus, our CRISPR KO screen experiment was performed selecting with etoposide 5 μ M or DMSO, etoposide solvent, for 14 days (Fig 1B). This treatment led to strong selection with less than 1% of cells surviving treatment (Supplementary Fig 1A). The cumulative frequency of sgRNA sequencing reads showed that the guides from etoposide were distinct from the counts obtained by sequencing the library plasmid (library) and those from Day 0 (post-puromycin selected cells) (Supplementary Fig 1B). We repeated the etoposide arm of the CRISPR experiment and validated the reproducibility of our CRISPR screen for most hits with both screens showing Spearman's $r^2=0.68$ ($p<0.0001$) both on the gene and sgRNA level (Supplementary List 1A). This screen showed that sgRNAs for the genes involved in ribosome and protein synthesis were over-represented in the etoposide as opposed to DMSO-treated cells ($p<1.0E^{-6}$, Fisher's exact test with Benjamini multiple hypothesis correction) (Fig 1C, Supplementary Fig 1C).

To identify the pathways implicated in glioma susceptibility to etoposide, we first analyzed genes that were enriched by etoposide compared to DMSO and/or Day 0. Using a cutoff for hit calling by sgRSEA enriched of $p<0.01$ (Wilcoxon), this analysis showed 979 genes

whose KO was uniquely enriched by etoposide compared to DMSO (etoposide>DMSO) (Fig 1D). 543 genes whose KO were enriched in etoposide compared to Day 0 (etoposide>Day 0) (Fig 1D). 397 genes whose KO was enriched and overlapped between etoposide >DMSO and in etoposide > Day 0 selected cells (Fig 1D, Supplementary List 1B). 236 genes whose KO was enriched in DMSO compared to Day 0, and these genes were not found to be enriched in etoposide > DMSO nor in etoposide > Day 0 comparison (Fig 1D). We used the 397 genes whose KO showed enrichment and overlapped between etoposide > DMSO and etoposide > Day 0 (Fig 1D) to perform a gene ontology analysis (DAVID). We found ontology themes related to translation as the most over-represented among the group of 397 genes (Fig 1E, Supplementary List 1B, and 1C). Amongst the genes enriched in translational machinery, the most over-represented were ribosomal subunit proteins, followed by mitochondrial ribosomal proteins and tRNA synthetase (Supplementary Fig 1C). Etoposide induces double-strand DNA breaks (5, 6) and on the other hand, gliomas are known to exhibit relatively high genome instability (19). Thus, we sought to investigate whether a component of the DNA damage and repair pathways is implicated in glioma susceptibility of TOP2 poisons. We found that 57 out of 348 genes previously implicated in DNA damage and repair (20) had their KO clone enriched in Etoposide>DMSO or in Etoposide>Day 0 (Fischer exact test for enrichment $p=2.3E^{-12}$), and 24 genes whose KO was enriched by etoposide compared to DMSO and Day 0 (Fisher exact test for enrichment $p=1.9E^{-7}$) (Supplementary List 1D). Using the 57 DNA damage and repair genes found to be enriched in etoposide > DMSO or in etoposide > Day 0 sample, we performed a gene ontology analysis, and found the theme of double strand DNA repair via homologous recombination to be enriched ($p=2.7E^{-6}$ Fisher's exact test with Benjamini multiple hypothesis corrections, implicating these genes in the known mechanism of TOP2 poisons inducing double- strand DNA breaks.

Other groups have performed genome-wide KO screens using etoposide in leukemia using CRISPR technology (20, 21) and also with other strategies for genome-wide screens to elucidate susceptibility to this drug in cancer (22,23). Whereas there are differences in the cancer cell line (e.g., leukemia vs. glioma), drug concentration, exposure period and analysis, our screen validated 20 out of 25 genes hits previously reported by these studies (Supplementary Fig 1D, Supplementary List 1D). In conclusion, the CRISPR screen revealed DNA damage pathways and translation as two separate processes that influence response to TOP2 poisons.

Glioma susceptibility to TOP2 poisons is associated with activation of DNA damage pathways following treatment.

We previously showed that susceptibility to TOP2 poison etoposide varies significantly across human cancer cell lines (7, 8). To investigate whether individual cancer cell line susceptibility to these drugs relates to the established mechanism of action, we compared the area under the dose response curve (AUC) of individual cell lines for etoposide versus doxorubicin, and versus that of other chemotherapy agents that are not TOP2 poisons ($n=665$, Cancer Cell Line Encyclopedia) (23,24). This analysis showed a high correlation of susceptibility to these TOP2 poisons across cancer cell lines, and similar results were observed when the analysis was restricted to gliomas (Fig 2A). Yet, no correlation was found

between either of the TOP2 poisons versus cisplatin or cytarabine, chemotherapeutics with a different mechanism of action. The results of DNA damage response theme represented by our CRISPR hits led us to hypothesize that individual variation in tumor susceptibility to TOP2 poisons relates to the mechanism of action for these drugs. To investigate whether differential etoposide susceptibility relates to DNA damage response, we quantified γ H2AX (phosphor-gamma H2AX) staining following etoposide treatment across glioma cell lines. We found a trend for a non-linear correlation between γ H2AX staining following etoposide with susceptibility to this drug across glioma cell lines ($r^2=0.96$, $p=0.068$ Fig 2B). Moreover, γ H2AX staining following etoposide treatment was associated with activated/cleaved caspase 3 across glioma cell lines ($r^2=0.98$, $p=0.0146$ Fig 2C).

Next, we sought to understand which DNA damage and repair genes were enriched in either of our screens. Genes involved in DNA damage response whose KO was enriched by etoposide compared to DMSO included TOP2A (Fig 2D and Supplementary Fig 2A), the canonical target of TOP2 poisons, as well as SMC6 and ERCC, which are cohesin and excision repair proteins known to interact with TOP2A and TOP2B (25). Genes from the Fanconi anemia pathway were also present in this list, including RAD1, RAD51, RAD51C, UHRF1 (Fig 2D). Analysis of genes involved in DNA damage and repair whose KO was selected by etoposide compared to Day 0 revealed FANCB and FANCE, which are components of core complexes of Fanconi repair machinery as the most enriched among DNA damage genes in etoposide vs Day 0 (Fig 2E). Thus, whereas several pathways related to DNA damage response were represented in the results of our screen, key members of the Fanconi anemia pathway were shown to be implicated in susceptibility to etoposide on these two separate CRISPR KO screen analyses.

FANCB is a key protein within the Fanconi anemia core complex. This protein has been previously established to play a role in the DNA damage and repair pathway that is activated following treatment with several chemotherapeutics (26). To validate our genome-wide screen results (Fig 2E), we performed KO of FANCB using a single guide CRISPR approach. We confirmed on-target cleavage by this sgRNA and reasonably ruled out the possibility of off-target genome editing on the locus that was predicted as the most likely off-target through a cleavage assay (27) (Supplementary Fig 2B). Western blot showed a decrease of FANCB protein levels in the population of FANCB KO cells edited by CRISPR (Fig 2F), which led to acquired resistance to both etoposide (Fig 2G) and doxorubicin. FANCB KO also led to a decrease in γ H2AX staining following etoposide treatment for 24 hrs. in contrast to an increase of this DNA damage signaling following etoposide in the control cells (Fig 2H and Supplementary Fig 2C–D). Given that TOP2 poisons induce double-strand DNA breaks, that our CRISPR KO screen revealed enrichment of double-strand DNA break repair pathway as an ontology theme, we performed immunofluorescence for 53BP1, a marker that is specific for activation of DNA damage response pathways for double-strand DNA breaks. We found that KO FANCB led to an increase in the number of 53BP1 dots per nucleus relative to wild type cells, in the absence of etoposide treatment (Supplementary Fig 2E–F). In this setting, adding etoposide did not further increase 53BP1 staining on cells that already have elevated 53BP1 due to FANCB KO.

Expression of ribosomal proteins predicts and influences glioma susceptibility to etoposide.

To discover biomarkers for TOP2 poisons, we first obtained a short list of candidate genes that are implicated by being associated with and directly influencing susceptibility to this drug. To do this, we overlapped 397 genes whose loss confers etoposide resistance from our CRISPR screens (etoposide>DMSO intersection with etoposide>/Day 0, with genes whose expression (35 glioma cell lines RNA Seq) correlates with susceptibility to etoposide. With this, we performed differential gene expression analysis of glioma cells with etoposide susceptibility data from CCLE, using $IC_{50} < 1 \mu M$ as a cutoff to define susceptible lines ($n=7$) and $IC_{50} > 10 \mu M$ ($n=11$) to define resistant glioma cell lines. These cutoffs were based on the rationale that systemic administration of etoposide leads to tumor concentration of 2–6 μM in human gliomas and sensitive gliomas might have a clinical response to this drug at this concentration (16, 17, 18). Using a $p < 0.01$ cutoff for significance of differential gene expression (susceptible vs resistant), 9 genes (RPS18, RPS11, RPS16, RPS6, RPL35A, POLR1C, RPP25L, C10orf2 and LYRM4) out of 397 whose KO was selected by etoposide on the CRISPR screen showed higher expression on susceptible glioma cell lines compared to resistant, with 6 of these genes being ribosomal proteins. The expression of these genes on susceptible cell lines ranged from 2.9–1650 transcripts per million (TPM). Robust expression of a gene facilitates its use as a biomarker, thus we focused on RPS18, RPS11, RPS16, as these were the top 3 genes with the highest expression on susceptible cell lines among 9 selected genes (Fig 3A–B). A gene expression analysis including all glioma cell lines that had available etoposide susceptibility and gene expression data from CCLE ($n=35$) confirmed a significant correlation between expression of these genes with etoposide susceptibility ($p < 0.001$, Supplementary Fig 3A). To explore whether the expression of RPS11, 16, and 18 can distinguish tumors that are susceptible to etoposide, we performed immunofluorescence staining for these markers in intracranial glioma xenografts, and found that RPS11 staining was stronger in the glioma lines MES83 and U251 (which was originated from the same human tumor as SNB19), cell lines susceptible to etoposide, intermediate expression in GBM43 which is less sensitive to this drug than the former lines, and no staining was found on GBM6 and GBM12, which exhibit resistance to this drug (Fig 3C). To validate the implication of RPS11 in etoposide-related cell death, we edited RPS11 in SNB19 using CRISPR. RPS11 gene editing and loss was confirmed with the cleavage assay (Supplementary Fig 3B), and a decrease of the protein by Western blot (Fig 3D). We then investigated the contribution of RPS11 to etoposide and doxorubicin susceptibility. Viability assay following treatment with these agents showed that RPS11 KO rendered glioma cells resistant to both drugs (Fig 3E–F). We then investigated the effect of RPS11 over-expression on response to etoposide on a resistant cell line. Using lentiviral vectors, we overexpressed RPS11 in GBM6, a resistant glioblastoma PDX (Supplementary Fig 3C) and we found that RPS11 over-expression leads to susceptibility to TOP2 poison etoposide (Supplementary Fig 3D).

We next determined the effect of RPS11 KO on translation. We labeled nascent proteins with Click-it OPP as previously described (28), and found that RPS11 KO and the drug-resistant phenotype of these cells was associated with impaired translation (Fig 3G). Taken together,

these results indicate that the ribosomal protein subunit 11 influences response to TOP2 poisons and protein synthesis.

Expression of ribosomal proteins is associated with cancers' response to TOP2 poisons.

To further explore the expression of these genes for susceptibility to TOP2 poisons, we expanded our analysis to different cancers. The expression of RPS11, RPS16, RPS18 was queried in 341 cancer cell lines from multiple cancers, defining cell lines as susceptible or resistant using the same IC50 cutoff as for our analysis in gliomas. Expression of RPS11, RPS16, RPS18 remained significantly higher on susceptible cell lines from multiple cancers relative to resistant lines and remained so for several individual cancer types ($p < 0.01$, Fig 4A, Supplementary List 2 and 3). As an example, expression of RPS11, 16, 18 was significantly higher in breast cancer cell lines that were susceptible to etoposide and doxorubicin, a relevant finding considering that doxorubicin is often used to treat this disease (Fig 4B–C,).

RPS11 modulates induction of APAF1 and apoptosis during etoposide-induced translational shut-down.

Previously, groups have reported chemo resistance phenotype induced by impaired ribosome biogenesis (29). Given that translational machinery and ribosomal proteins were implicated in etoposide susceptibility, we determined protein synthesis following treatment with this drug across multiple glioma cell lines. We found that cell lines susceptible to TOP2 poisons (SNB19, U251), showed a decrease in nascent proteins following etoposide treatment. In contrast, GBM6 and GBM12 which are resistant to TOP2, showed no decrease in nascent proteins following etoposide (Fig 5A, Supplementary Fig 4A–C). RPS11 KO cells had a similar increase in γ H2AX and 53BP1 foci following etoposide treatment as that seen for SNB19 wild-type or non-targeting CRISPR control cells (Fig 5B), suggesting that RPS11's involvement in cell death from TOP2 poisons is not mediated through activation of DNA damage response activation following treatment with these drugs.

We hypothesized that RPS11 expression modulates apoptosis, as this process is triggered by DNA damage following etoposide. Whole genome CRISPR screen revealed that KO of APAF1, a key element of the apoptosis machinery (30,31) that is activated following DNA damage, had its KO clones selected by etoposide compared to DMSO on our CRISPR screen (Fig 5C). We then investigated the effect of RPS11 KO on APAF1 expression and how this is affected by etoposide treatment. APAF1 transcript had a significant induction following etoposide treatment in SNB19 WT and non-targeting control cells, whereas no significant expression changes were found in RPS11 KO cells (Fig 5D). Comparison of APAF1 mRNA following etoposide between wild-type cells versus RPS11 KO suggest transcriptional modulation of this gene by RPS11. Interestingly APAF1 protein levels increased following etoposide treatment in SNB19 wild-type and non-targeting control cells, whereas etoposide treatment led to a decrease APAF1 protein in RPS11 KO cells (Fig 5E). To investigate whether APAF1 induction by etoposide is specific to susceptible glioma lines, we compared its expression following treatment with this drug between susceptible cell line SNB19 and resistant cell line GBM12, and confirmed its induction is only seen in the former (Fig 5F, Supplementary Fig 4D), which we previously showed suffers H2AX

phosphorylation and apoptosis following this treatment. These results support that RPS11 is necessary for APAF1 up-regulation following etoposide in susceptible glioma cells at both transcript as well as protein levels, in the context of a global shut-down of protein synthesis following treatment with this drug.

Since APAF1 is involved at the initial phases of the apoptotic process, we explored if the pro and anti-apoptotic genes BID and BCL2 (32) downstream of APAF1 show differential expression in susceptible and resistant GBM upon TOP2 treatment. We treated a panel of GBM cell lines with and without etoposide for 24 hrs. and labelled them for BID and BCL2. These studies revealed that susceptible glioma cells show increased BID expression compared to the resistant cells. Conversely, following etoposide treatment, resistant cell lines GBM6 and GBM12 showed an increase in anti-apoptotic protein BCL2 that was not observed in susceptible cell lines (Supplementary Fig 5A–B). Taken together, our results indicate that in susceptible glioma cells, RPS11 confers susceptibility to TOP2 poisons is associated with modulation of APAF1 induction (Supplementary Fig 5C), with subsequent activation of apoptosis following treatment with these drugs (31,32).

Discussion

We performed a genome scale CRISPR KO screen and combined its results with susceptibility and gene expression data from different cell lines. This approach allowed unbiased investigation of individual genes as variables that account for individual tumor susceptibility to TOP2 poisons in glioma. Our CRISPR screen also revealed novel functional themes that play a role in response to this chemotherapy. In particular, we found that ribosomal subunit proteins and translation-related machinery are required to respond to these drugs.

We validated the involvement of several genes previously shown to play a role in TOP2 poison mechanism of action. These include, TOP2A, SMC6 and other genes are known to be involved in the susceptibility of cancers to TOP2 poisons (5, 6, 7, 8, 21, 22, 34). This experiments also implicated DNA damage response and, FANCB and the Fanconi anemia pathway (26), as a key player in DNA damage response activation and susceptibility to etoposide.

Previous work implicated DNA damage response in the mechanism of action of TOP2 poisons (5, 6) yet to our knowledge differences in susceptibility have not been linked to this process before. Our results showed a trend for a correlation between H2AX phosphorylation following etoposide and susceptibility to this drug across glioma cell lines, suggesting that whereas DNA damage response is important for etoposide susceptibility, there might be other variables (e.g. expression of protein synthesis-related genes) that explain differences in susceptibility across tumors. We observed that loss of FANCB increases the baseline activation of double-strand DNA damage pathways as shown by H2AX phosphorylation and 53BP1 foci, yet these pathways do not further increase following treatment with TOP2 poisons. Thus, this suggests that the loss of FANCB leads to etoposide resistance as it leads to lack of H2AX phosphorylation following treatment with this chemotherapy drug. This is consistent with previous reports showing that H2AX phosphorylation is involved on DNA

fragmentation during apoptosis (46). We conclude therefore that Fanconi anemia group of proteins in particular FANCB, is a major regulator of DNA damage response following TOP2 poison in gliomas. Yet, FANCB is only deleted or genetically altered in in 0.8% of glioblastomas (TCGA), and therefore it is unlikely that it contributes to variable susceptibility to TOP2 poisons across tumors. Whereas the DNA damage pathways are clearly implicated in susceptibility to TOP2 poisons, many of the genes from these pathways are induced after DNA damage, and thus their baseline expression is not informative of susceptibility, rendering these poor predictive biomarkers.

Our study provides evidence that susceptibility to TOP2 poisons implicates genes that modulate translation. Our results suggest that RPS11 and modulation of translation in susceptibility to etoposide cannot be explained through modulation of DNA damage response activation (e.g. γ H2AX/53BP1 foci). Indeed, RPS11 KO led to impairment of translation and acquired resistance to etoposide and doxorubicin but had no significant effect on DNA damage response activation following etoposide treatment.

Our study directly implicates several ribosomal subunit proteins in response to etoposide. RPS proteins have been investigated in response to chemotherapy, for example, the loss of RPS19 conferred cytoprotection to TOP1 agent camptothecin (29, 21), previously showed RPS21, RPS27L, RPS24, RPS6KB2, RPS4Y2 and RPS4Y1 to confer susceptibility to etoposide in acute pro-myelocytic leukemia cell line (HL60).

Triggering of apoptosome machinery in the context of TOP2 poison and DNA damaging agents has also been previously reported (30, 31). On the other hand, the induction of apoptosis by etoposide has been linked to p53 (29, 35). In our CRISPR screen, KO of p53 was not selected by etoposide. Yet, we showed that expression of RPS11 was necessary for induction of apoptotic protein APAF1 following etoposide treatment, in the context of a robust translational shutdown that is only seen in susceptible cell lines. Given this and the fact that APAF1 KO clones were selected by our CRISPR screen, we conclude that baseline expression of RPS11 ribosomal subunit protein is necessary for induction of APAF1, and triggering of apoptosis in response to etoposide, in spite of the global translational shutdown susceptible cells. Nevertheless, we acknowledge that this process is complex and might involve other mechanisms that we did not explore.

Etoposide and TOP2 poisons are highly efficacious chemotherapy agents. Yet, differences in resistance across tumors and the toxicity associated with such treatments undermines the risk/benefit ratio that this therapy can offer to individual patients (36, 37,38, 39, 40, 41). To overcome this, biomarkers for etoposide and doxorubicin response are necessary, but non-existent. Our work suggests that ribosomal subunits and in particular RPS11 expression might serve as predictive biomarkers for TOP2 poisons sensitivity in gliomas and across different kinds of tumors. Future prospective studies for clinical validation are necessary to establish the accuracy and clinical value of these biomarker candidates.

Taken together, we presented evidence that suggests that loss of FANCB and RPS11 led to resistance to TOP2 poisons. However, some questions remain. For instance, we did not investigate whether there is an epistatic interaction between FANCB and RPS11. Important

follow up questions that remain unanswered is whether and how DNA damage response relates to modulation of translation in the context of response to etoposide.

TOP2 poisons are gaining relevance as a promising therapy for gliomas. Several previous and ongoing trials have evaluated TOP2 poisons for gliomas (reviewed in Mehta, Awah & Sonabend (7)). With the advancement of technologies that improve the delivery of drugs across the blood-brain barrier, the interest in doxorubicin for treatment of gliomas has surged (there are 12 clinical trials evaluating doxorubicin for gliomas listed on clinicaltrials.gov). For instance, ongoing trials are evaluating doxorubicin for glioblastomas using MRI-guided laser therapy to open the blood-brain barrier and enhance the penetration of this drug to the human brain in children and adults ([NCT02372409](https://clinicaltrials.gov/ct2/show/study/NCT02372409) and [NCT01851733](https://clinicaltrials.gov/ct2/show/study/NCT01851733) clinicaltrials.gov). On the other hand, ultrasound- based opening of the blood-brain barrier is an emerging technology to enhance drug delivery to the brain for glioblastomas (47,48,49). This approach is now being tested on several clinical trials (49,50,53,51,52) and has been shown to be feasible and effective for doxorubicin delivery in several pre-clinical models of gliomas and in some early phase clinical trials (50–53).

A limitation of our current study is that the proposed predictive biomarkers we present were not validated in clinical datasets. The available clinical datasets had multiple censored data points, lack of clear treatment annotation, and thus, were not a reliable source for a rigorous analysis of these biomarkers. The value of RPS11 and other putative biomarkers discovered on this current study will need to be prospectively investigated prospectively on future clinical trials.

The use of TOP2 poisons based on individual tumor biology as opposed to histological criteria might enhance efficacy achieved by these drugs on specific patients, avoid unnecessary drug-related toxicity in patients whose tumor will not respond, and could open therapeutic options for aggressive malignancies such as gliomas. Our work sets the foundation for this precision medicine approach for the use of TOP2 poisons for gliomas and adds to the body of evidence suggesting that the study of individual tumor biology rather than global cancer phenotype might provide more effective therapeutic interventions.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

This work was funded by 5DP5OD021356-05 (AS), P50CA221747 SPORE for Translational Approaches to Brain Cancer (AS), and Developmental funds from The Robert H Lurie NCI Cancer Center Support Grant #P30CA060553 (AS), and generous philanthropic support from Dan and Sharon Mocer. We thank Dr Ichiro Nakano (University of Alabama), Dr. Charles David James (Northwestern University) and Dr. Shi-Yuan Cheng (Northwestern University), for the kind gift of the GBM xenografts. We thank Dr. Peng Zhang (Northwestern University) for technical support with culture of GBM PDX. We thank Synthego CA, USA for the gifts of RPS11 sgRNA guides. γH2AX imaging work was performed at the Center for Advanced Microscopy/Nikon Imaging Center and RHLCCC - Flow Cytometry Core, Northwestern University supported by NCI CCSG P30 CA060553 awarded to the Robert H Lurie Comprehensive Cancer Center. BG was supported by the NVKP 16-1-2016- 0037 grant.

References

1. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial. *JAMA*, 2017 318(23): p. 2306–2316. [PubMed: 29260225]
2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell*, 2010 17(1): p. 98–110. [PubMed: 20129251]
3. Sturm D., Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell*, 2012 22(4): p. 425–37. [PubMed: 23079654]
4. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA et al., Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell*, 2016 164(3): p. 550–63. [PubMed: 26824661]
5. Nitiss JL, Targeting DNA topoisomerase II in cancer chemotherapy. *Nat Rev Cancer*, 2009 9(5): p. 338–50. [PubMed: 19377506]
6. Nitiss JL, DNA topoisomerase II and its growing repertoire of biological functions. *Nat Rev Cancer*, 2009 9(5): p. 327–37. [PubMed: 19377505]
7. Mehta A, Awah CU, and Sonabend AM, Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy. *Front Neurol*, 2018 9: p. 459. [PubMed: 29988316]
8. Sonabend AM, Carminucci AS, Amendolara B, Bansal M, Leung R, Lei L, et al., Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. *Neuro Oncol*, 2014 16(9): p. 1210–9. [PubMed: 24637229]
9. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A et al., Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. *Neuro Oncol*, 2007 9(3): p. 354–63. [PubMed: 17452651]
10. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S et al., Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. *Br J Cancer*, 2009 101(12): p. 1986–94. [PubMed: 19920819]
11. Leonard A and Wolff JE, Etoposide improves survival in high-grade glioma: a meta-analysis. *Anticancer Res*, 2013 33(8): p. 3307–15. [PubMed: 23898097]
12. Doench JG Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF et al., Optimized sgRNA design to maximize activity and minimize off- target effects of CRISPR-Cas9. *Nat Biotechnol*, 2016 34(2): p. 184–191. [PubMed: 26780180]
13. Hsu PD, Lander ES, and Zhang F, Development and applications of CRISPR-Cas9 for genome engineering. *Cell*, 2014 157(6): p. 1262–78. [PubMed: 24906146]
14. Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD et al., Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. *Nat Protoc*, 2017 12(4): p. 828–863. [PubMed: 28333914]
15. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen T et al., Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science*, 2014 343(6166): p. 84–87. [PubMed: 24336571]
16. Pitz MW, Desai A, Grossman SA, Blakeley JO., Tissue concentration of systemically administered antineoplastic agents in human brain tumors. *J Neurooncol*, 2011 104(3): p. 629–38. [PubMed: 21400119]
17. Zucchetti M., Rossi C, Knerich R, Donelli MG, Butti G, Silvani V et al., Concentrations of VP16 and VM26 in human brain tumors. *Ann Oncol*, 1991 2(1): p. 63–6.
18. Stewart DJ, Richard MT, Hugenholtz H, Dennery JM, Belanger R, Gerin-Lajoie J et al., Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. *J Neurooncol*, 1984 2(2): p. 133–9. [PubMed: 6481426]

19. Koschmann C., Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D et al., ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. *Sci Transl Med*, 2016 8(328): p. 328ra28.
20. Michlits G., Hubmann M, Wu SH, Vainorius G, Budusan E, Zhuk S et al., CRISPR-UMI: single-cell lineage tracing of pooled CRISPR-Cas9 screens. *Nat Methods*, 2017 14(12): p. 1191–1197. [PubMed: 29039415]
21. Wang T., Wei JJ, Sabatini DM, Lander ES, Genetic screens in human cells using the CRISPR-Cas9 system. *Science*, 2014 343(6166): p. 80–4. [PubMed: 24336569]
22. Wijdeven RH, Pang B, van der Zanden SY, Qiao X, Blomen V, Hoogstraat M et al., Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer. *Cancer Res*, 2015 75(19): p. 4176–87. [PubMed: 26260527]
23. Cancer Cell Line Encyclopedia, C. and C. Genomics of Drug Sensitivity in Cancer, Pharmacogenomic agreement between two cancer cell line data sets. *Nature*, 2015 528(7580): p. 84–7. [PubMed: 26570998]
24. Forbes SA, Beare D, Bindal N, Bamford S, Ward S, Cole CG et al., COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer. *Curr Protoc Hum Genet*, 2016 91: p. 10 11 1–10 11 37.
25. Uuskula-Reimand L., Hou H, Samavarchi-Tehrani P, Rudan MV, Liang M, Medina-Rivera A et al., Topoisomerase II beta interacts with cohesin and CTCF at topological domain borders. *Genome Biol*, 2016 17(1): p. 182. [PubMed: 27582050]
26. Ceccaldi R, Sarangi P, and D'Andrea AD, The Fanconi anaemia pathway: new players and new functions. *Nat Rev Mol Cell Biol*, 2016 17(6): p. 337–49. [PubMed: 27145721]
27. Guschin DY, Waite AJ, Katibah GE, Miller JC, Holmes MC, Rebar EJ., A rapid and general assay for monitoring endogenous gene modification. *Methods Mol Biol*, 2010 649: p. 247–56. [PubMed: 20680839]
28. Forester CM, et al. Revealing nascent proteomics in signaling pathways and cell differentiation. *Proc Natl Acad Sci U S A*, 2018 115(10): p. 2353–2358. [PubMed: 29467287]
29. Sapio RT, Nezdyur AN, Krevetski M, Anikin L, Manna VJ, Minkovsky N et al. Inhibition of post-transcriptional steps in ribosome biogenesis confers cytoprotection against chemotherapeutic agents in a p53-dependent manner. *Sci Rep*, 2017 7(1): p. 9041. [PubMed: 28831158]
30. Pop C and Salvesen GS, The nematode death machine in 3D. *Cell*, 2005 123(2): p. 192–3. [PubMed: 16239138]
31. Pop C, Timmer J, Sperandio S, Salvesen GS., The apoptosome activates caspase-9 by dimerization. *Mol Cell*, 2006 22(2): p. 269–75. [PubMed: 16630894]
32. Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A, Korsmeyer S., A role for proapoptotic BID in the DNA-damage response. *Cell*, 2005 122(4): p. 579–91. [PubMed: 16122425]
33. Kanarek N., Keys HR, Cantor JR, Lewis CA, Chan SH, Kunchok T et al., Histidine catabolism is a major determinant of methotrexate sensitivity. *Nature*, 2018 559(7715): p. 632–636. [PubMed: 29995852]
34. Mjelle R., Hegre SA, Aas PA, Slupphaug G, Drabløs F, Saetrom P et al., Cell cycle regulation of human DNA repair and chromatin remodeling genes. *DNA Repair (Amst)*, 2015 30: p. 53–67. [PubMed: 25881042]
35. Haapaniemi E., Botla S, Persson J, Schmierer B, Taipale J., CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. *Nat Med*, 2018 24(7): p. 927–930. [PubMed: 29892067]
36. Barnoud D., Pinçon C, Bruno B, Béné J, Gautier S, Lahoche A et al., Acute kidney injury after high dose etoposide phosphate: A retrospective study in children receiving an allogeneic hematopoietic stem cell transplantation. *Pediatr Blood Cancer*, 2018 65(7): p. e27038. [PubMed: 29528179]
37. Girling DJ, Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. *Lancet*, 1996 348(9027): p. 563–6. [PubMed: 8774567]
38. Franceschi E., Cavallo G, Scopece L, Paioli A, Pession A, Magrini E et al., Phase II trial of carboplatin and etoposide for patients with recurrent high- grade glioma. *Br J Cancer*, 2004 91(6): p. 1038–44. [PubMed: 15305187]

39. Krisp C., Parker R, Pascovici D, Hayward NK, Wilmott JS, Thompson JF et al., Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. *Br J Cancer*, 2018.
40. Moreno P., Jiménez-Jiménez C, Garrido-Rodríguez M, Calderón-Santiago M, Molina S, Lara-Chica M et al., Metabolomic profiling of human lung tumor tissues: nucleotide metabolism as a candidate for therapeutic interventions and biomarkers. *Mol Oncol*, 2018.
41. Tsai CH, Chen YT, Chang YH, Hsueh C, Liu CY, Chang YS et al., Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens. *Oncotarget*, 2018 9(56): p 30731–30747. [PubMed: 30112103]
42. Dennis G Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al., DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol*, 2003 4(5): p. P3. [PubMed: 12734009]
43. Subramanian A., Kuehn H, Gould J, Tamayo P, Mesirov JP., GSEA-P: a desktop application for Gene Set Enrichment Analysis. *Bioinformatics*, 2007 23(23): p. 3251–3. [PubMed: 17644558]
44. Miller AD and Buttimore C, Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. *Mol Cell Biol*, 1986 6(8): p. 2895–902. [PubMed: 3785217]
45. Winter J. Scherwing M, Pelz O, Rauscher B, Zhan T, Heigwer F et al. CRISPRAnalyzeR: Interactive analysis, annotation and documentation of pooled CRISPR screens. *BioRxiv* 2017
46. Lu C, Zhu F, Cho YY, Tang F, Zykova T, Ma WY et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. *Mol Cell*. 2006;23(1):121–32. [PubMed: 16818236]
47. Idhah A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G et al. Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. *Clin Cancer Res*. 2019 25(13):3793–3801. [PubMed: 30890548]
48. Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. *Sci Transl Med*. 2016;8(343):343re2. doi: 10.1126/scitranslmed.aaf6086
49. Sonabend AM, Stupp R. Overcoming the blood brain barrier with an implantable ultrasound device. *Clin Cancer Res*. 2019 25(13):3750–3752. doi: 10.1158/1078-0432. [PubMed: 31076548]
50. Mainprize T, Lipsman N, Huang Y, Meng Y, Bethune A, Ironside S et al. Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study. *Sci Rep*. 2019; 9(1):321. doi: 10.1038/s41598-018-36340-0. [PubMed: 30674905]
51. Lin YL, Wu MT, Yang FY. Pharmacokinetics of doxorubicin in glioblastoma multiforme following ultrasound-Induced blood-brain barrier disruption as determined by microdialysis. *J Pharm Biomed Anal*. 2018; 149:482–487. doi: 10.1016/j.jpba.2017.11.047 [PubMed: 29175555]
52. Sun T, Zhang Y, Power C, Alexander PM, Sutton JT, Aryal M et al. Closed-loop control of targeted ultrasound drug delivery across the blood- brain/tumor barriers in a rat glioma model. *Proc Natl Acad Sci U S A*. 2017;114(48): E10281–E10290. doi: 10.1073/pnas.1713328114. [PubMed: 29133392]
53. Alli S, Figueiredo CA, Golbourn B, Sabha N, Wu MY, Bondoc A et al. Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery. *J Control Release*. 2018; 281:29–41. doi: 10.1016/j.jconrel.2018.05.005. [PubMed: 29753957]




Fig 1: CRISPR screen in glioma cells reveals genes that confer susceptibility to etoposide
(A) Etoposide dose response curves of 11 human glioma cell lines treated with etoposide (2–40 μM) and DMSO for 72hrs. **(B)** Schematic depiction of the CRISPR screen experiment performed in this study. Vector containing 76,441 sgRNA library expressing Cas9a were packaged into lentivirus, which was spinfected into SNB19 cells. The transfected cells were selected with puromycin for 96hrs. Cells were expanded and split into etoposide treatment and DMSO for 14 days with 1×10^8 cells per condition (1298X coverage). Unique barcoded primers were used to amplify the library, puromycin/Day 0, DMSO and etoposide selected guides. These samples were pooled and sequenced. sgRNA enrichment was analyzed using CRISPRAnalyzer (45). All experiment was done in two independent replicates except for DMSO that was performed once. **(C)** Scatter plot depicts the genes with highest sgRNA enrichment by etoposide ($p < 0.000001$). Ribosomal and tRNA synthetase genes marked in purple. Red genes represent those related to ubiquitin, proteasome, tubulin and RNA Polymerase II subunits. The rest of sgRNA are represented in black and the non-targeting controls in gray. **(D)** Venn diagram show number of genes that were enriched in comparisons between different experimental conditions. For this $p < 0.01$ sgRSEA enriched was used as a cutoff for hit calling (Wilcoxon). **(E)** Bar chart shows the enriched gene ontology themes from the 397 genes whose KO enrichment overlapped between etoposide > DMSO and etoposide > puromycin. Benjamini Hochberg adjusted pvalue for gene ontology enrichment cutoff, $p = 0.001$.




Fig 2: DNA damage and repair response contribute to GBM shared genetic susceptibility to TOP2 poisons

(A) Scatter plot for susceptibility (area under the curve for dose response curve, AUC) to etoposide and doxorubicin across human cell lines from multiple cancers (n=665, left), and the human glioma cell line subset (n=43, right) from COSMIC dataset²⁴, correlation determined by Spearman's test (B) Non- linear regression shows a trend for correlation between DNA damage response (yH2AX staining) and etoposide susceptibility for different gliomas captured by the area under the curve (AUC) based on the Pearson's correlation (Exponential growth equation). (C) Activated/cleaved caspase 3 was determined through flow cytometry following 1, 6 and 24 hr of etoposide 5 μ M treatment. Data was normalized over DMSO treatment for each time point. Glioma cell lines ranked by etoposide susceptibility (most susceptible left, most resistant right). (D) Scatter plot shows the highest enriched DNA damage and repair genes enriched by etoposide compared to DMSO ($p < 0.001$) or compared to Day 0/puromycin ($p < 0.01$) SgRSEA enriched (Wilcoxon test) (E). For (D, E), the DNA damage and repair genes are ranked in order of enrichment. Genes in asterisks belong to the Fanconi anemia group of proteins. (F) Western blot for FANCB in the KO cells, wild type SNB19 and two clones that were edited with non-targeting control guides. Quantified against normalized GAPDH ($***p < 0.001$). (G) Viability of SNB19 WT, SNB19 non-targeting control 1 (NT1), and SNB19 FANCB KO following treatment with DMSO or etoposide 5 μ M for 72hrs. T- test p value against FANCB vs WT SNB19 or NT1 or NT2 has ($***p < 0.00001$, two-tailed t-test). (H) Graph shows quantified count of yH2AX foci on SNB19 wild type, SgNT1 control and SgFANCB treated with and without etoposide ($***p < 0.0001$, zero-inflated negative binomial model).




Fig 3: Ribosomal subunit proteins controls GBM susceptibility to TOP2 poisons and are biomarker for favorable response.

(A) Venn diagram shows the triage of three big data sets combination (CRISPR hits p<0.01, 35 glioma cell lines RNA Seq, 35 glioma cell lines IC50/AUC) to define putative biomarker. Bar chart shows expression differences between glioma cell lines (CCLE) that are sensitive (IC50 <1μM) versus resistant (IC50 >10μM) to etoposide for RPS11(*p=0.01), RPS16 (* p=0.0057, unpaired t-test), RPS18 (* p=0.0004, Mann Whitney test). (B) Violin plots show the log2 fold change enrichment of RPS11, 16, 18 in etoposide compared to DMSO and the non-targeting controls from CRISPR screen. (C) Immunofluorescence staining for RPS11, RPS16, RPS18 across intracranial glioma xenografts (top) with variable etoposide susceptibility determined by dose-response curves obtained *in vitro* for 72hrs (bottom). (D) Western blot for RPS11 on RPS11 KO SNB19 cells compared to the non-targeting controls edited SNB19 cells. Densitometry quantified (**p=0.01, unpaired t-test). (E) Viability assay for RPS11 KO cells (*** p=0.001), and control SNB19 cells to 5μM etoposide (left) and (f) 5μM doxorubicin (*** p=0.001). For (F), viability data was normalized for DMSO condition for each clone. (G) Histogram showing protein synthesis across RPS11 KO (purple), and non-targeting controls (orange), quantified in bar chart (**p=0.001, unpaired t-test).




Fig 4: Ribosomal subunit proteins 11, 16, and 18 are influences etoposide response across cell lines for different cancers.

(A) Bar charts shows RPS11 (** $p=0.0058$, Mann Whitney test), RPS16 (**** $p<0.0001$ Mann Whitney test), RPS18 (**** $p<0.0001$, Mann Whitney test) expression with IC50 (<1 μM, N= 132 vs >10 μM, N=209) across 341 cancer cell lines. **(B)** Bar charts shows RPS11 (** $p=0.0055$, two tailed t-test), RPS16 (* $p=0.0161$, two-tailed t-test), RPS18 (**** $p<0.0001$, ordinary one-way Anova) expression with IC50<1 μM vs >10 μM etoposide for breast cancer cell lines. **(C)** Bar charts shows RPS11, RPS16 and RPS18 $p<0.0001$, ordinary one-way Anova expression with IC50≤0.2 μM vs >1 μM for breast cancer cell lines treated with doxorubicin.




Fig 5: RPS11 confers susceptibility to TOP2 poisons by controlling nascent proteins and upregulating pro-apoptosome machinery APAF1.

(A) Bar plots shows median fluorescence intensity of nascent protein synthesis across GBM with and without etoposide for 24hrs. (B) γ H2AX foci count on SNB19 WT cells, NT control cells or RPS11 KO with and without etoposide treatment quantified foci (below) (**** $p < 0.0001$, zero inflated negative binomial model).

(C) Bar plot shows the selection of two separate sgRNA for pro-apoptosome gene APAF1 in etoposide compared to DMSO from the genome-wide CRISPR screen ($p = 0.02$). (D) Bar plot shows APAF1 mRNA transcript (qRT-PCR) on sgRPS11 KO, WT SNB19 and NT controls treated with and without etoposide for 24hrs (*** $p = 0.001$, unpaired two-tailed t-test). (E) Western blot shows the reduction of APAF1 expression in RPS11 edited cells treated with etoposide but an increase in APAF1 in wild type and the non-targeting controls treated with etoposide (top). Bar plots show the quantification of the APAF1 expression both under etoposide and the DMSO treated cells normalized against GAPDH (bottom). (F) Bar plot shows median fluorescence intensity of APAF1 between SNB19 (right ** $p < 0.0098$, unpaired t-test with Welch's correction) and GBM12 (**** $p < 0.0001$, unpaired t-test) treated with and without etoposide for 24hrs.